ClinicalTrials.gg
TerminatedNCT03910907Updated Jun 2, 2023

Comparison of Standard of Care Guidelines for Mycoplasma Genitalium Infections Among Men With Non-gonococcal Urethritis

An observational study in Mycoplasma Genitalium Infection, sponsored by University of Alabama at Birmingham. Terminated at 1 site in United States. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-06-02.

Sponsored by University of Alabama at Birmingham · Observational

How we know

Why this study was terminated
Covid

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 99 Years
Sex
Male
01

Study summary

The purpose of this protocol is to determine the difference in clearance of Mycoplasma genitalium (MG) when using the Australian management protocol versus the current Centers of Disease Control (CDC) treatment guidelines for US standard of care (SOC), to determine the proportion of men from the Deep South, with NGU attributable to MG, and to determine the proportion of MG cases that harbor the macrolide-resistance associated with mutation.

Read the detailed description

Mycoplasma genitalium (MG) has been associated with non-gonococcal urethritis (NGU) in many populations and the prevalence of MG strains with macrolide-resistance associated gene mutations is increasing . While no MG diagnostic assays have FDA clearance in the United States (US), treatment for NGU is primarily focused on managing potential infection with Chlamydia trachomatis (CT) using single dose 1 gm Azithromycin (a macrolide class of drug). Without testing for MG that might alter NGU treatment strategies, the current paradigm may be contributing to selective pressure resulting in increased macrolide resistance in MG. In Australia, awareness of the prevalence of MG and macrolide resistance-associated mutations has been facilitated by an approved diagnostic test manufactured by SpeeDx. Ltd. As a result of the epidemiologic information generated by this diagnostic tool [MG ResistancePlus (MRP) Assay], the Australian Sexual Health Alliance, who publish the Australian Sexually Transmitted Infection (STI) Management Guidelines for Use in Primary Care, have revised the management of men with NGU and MG infection. The new management guidelines include initial treatment of NGU with doxycycline, and concomitant testing for MG and macrolide resistance, with subsequent treatment for MG infected patients according to resistance results. We propose using the MRP assay in a population of men with NGU to determine the clinical impact of the Australian treatment strategy compared to the current standard of care for NGU on clearance of MG infection.

02

Conditions studied

  • Mycoplasma Genitalium Infection

Keywords

  • mycoplasma genitalium
  • urethritis
  • NGU
  • treatment
03

In context

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men with non-gonoccocal

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presenting with symptoms of urethritis (dysuria and/or urethral discharge)

Exclusion criteria

Exclusion Criteria:

  • Non-English speaking
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Standard of care

    Men treated for mycoplasma according to standard of care

    Drug: Comparison of two standard of care regimens

  • Standard of care plus

    Men treated for mycoplasma according to standard of care with regimen selected based on laboratory detection of resistance markers

    Drug: Comparison of two standard of care regimens

Interventions

  • DrugComparison of two standard of care regimens

    Treatment according to results of laboratory detection of resistance markers

06

What researchers measure

Primary outcomes

  1. Participants with Molecular Clearance

    DNA negative for mycoplasma

    Time frame: 90 days

Secondary outcomes

  1. Positive Participants with Macrolide-Resistant Mycoplasma

    DNA positive for macrolide-resistant mycoplasma

    Time frame: 90 days

07

Study locations

1 site
  • UAB
    Birmingham, Alabama 35294, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Mar 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2019
First posted
Apr 10, 2019
StartActual
Nov 19, 2019
Primary completionActual
Mar 20, 2020
CompletionActual
Mar 20, 2020
Last update
Jun 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03910907
Responsible party
Barbara Van Der Pol (Primary Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Apr 10, 2019
Start date
Nov 19, 2019
Primary completion
Mar 20, 2020
Completion
Mar 20, 2020
Last update
Jun 2, 2023

Study contacts

Barbara Van Der Pol, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion